Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia

Trial Profile

Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Linezolid (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections; Pneumonia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms UGENT-LIMOP
  • Most Recent Events

    • 15 Aug 2017 Status changed from recruiting to completed.
    • 03 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 03 Jun 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top